

Q2 2022 Results

25 August 2022

CHRISTER NORDSTEDT MD PhD, ACTING CEO
ROBERT MAIORANA, ACTING CFO



Forward-looking statement

Important notice

The information in this presentation shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities referred to herein in any jurisdiction in which such offer, solicitation or sale would require preparation of further prospectuses or other offer documentation, or be unlawful prior to registration, exemption from registration or qualification under the securities laws of any such jurisdiction.

No representation or warranty expressed or implied is made as to, and no reliance should be placed on the fairness, accuracy, completeness or correctness of the information or opinion contained herein.

The information in this presentation may not be forwarded or distributed to any other person and may not be reproduced in any manner whatsoever. Any forwarding, distribution, reproduction, or disclosure of this information in whole or in part is unauthorized. Failure to comply with this directive may result in a violation of the Securities Act or the applicable laws of other jurisdictions.

Forward looking statements

This presentation contains forward-looking statements that reflect management's current views with respect to certain future events and potential financial performance. Although Vivesto believes that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will prove to have been correct. Accordingly, results could differ materially from those set out in the forward-looking statements as a result of various factors.

Important factors that may cause such a difference for Vivesto include but are not limited to: (i) the macroeconomic development, (ii) change in the competitive climate and (iii) change in interest rate level.

This presentation does not imply that Vivesto has undertaken to revise these forward-looking statements, beyond what is required by applicable law or applicable stock exchange regulations if and when circumstances arise that will lead to changes compared to the date when these statements were provided.

Today's speakers



CHRISTER NORDSTEDT MD PhD
Acting Chief Executive Officer



ROBERT MAIORANA
Acting Chief Financial Officer

Q2 results – operational updates

- Daniel Tesfa was appointed Chief Medical Officer
- Vivesto signed an agreement with leading US contract research organisation Visikol Inc. to evaluate anti-cancer drug formulations using, among other things, its proprietary drug delivery platforms
- At the Annual General Meeting Hege Hellström and Peter Zonabend were re-elected to the Board and Pål Ryfors and Roger Tell were elected as new Board members. Anders Härfstrand, Andrea Buscaglia and Birgit Stattin Norinder declined re-election. Peter Zonabend was elected as Chairman of the Board
- Vivesto's Board of Directors agreed with the company's CEO, Francois Martelet, to mutually terminate his employment as of 21 July 2022
- Robert Maiorana was appointed acting CFO, with effect from July 1, 2022

Post period end

- Christer Nordstedt MD PhD was appointed acting CEO
- Vivesto winds down activities in Russia
- Vivesto noted the launch of Apealea[®] in Germany by Inceptua

Positioning Vivesto for the next stage of its growth...



Building our capabilities to attract innovative assets


Accelerating Business Development and in-licensing

Securing our financial position well capitalised with no debt

Reducing business risks and operating expenditure

New leadership Chairman in place; CEO & CFO being recruited

Apealea[®] launches and driving our clinical pipeline



Our areas of focus

Oncology R&D

in-licensed & wholly-owned development-stage assets

- Cantrixil
- Docetaxel micellar
- Strategic pipeline development (string of pearls)



Commercial

revenues from out-licensed products and technologies

- Apealea® for ovarian cancer
- XR-17™ / XR-18 drug delivery technologies
- Animal health assets for partnering



Aiming to build critical mass in cancer

Significantly broadened pipeline by implementing 'string of pearls' strategy

Product	Indication	Pre-clinical	Phase 1	Phase 2	Phase 3	Registration / approval	Commercial Launch	Geography	
Apealea® (paclitaxel micellar)	Ovarian cancer	→							EU/EEA
Apealea® (paclitaxel micellar)	Ovarian cancer	→						US	
Cantrixil IP	Ovarian cancer	→						Global	
Docetaxel micellar	Prostate cancer	→						EU/EAA	
Cantrixil New Formulation	Ovarian cancer	→						Global	



Cantrixil – progressing towards a Phase II

- Global rights to first-in-class Cantrixil licensed from Kazia Therapeutics Limited (ASX:KZA) March 2021
- Tubulin-binding small molecule with potent cytotoxicity against ovarian cancer stem cells, ovarian somatic cancer cells, resistant to standard of care chemotherapies
 - Potential to improve outcome in earlier stage of relapsed ovarian cancer
 - Acceptable safety profile in I.P. use
- Orphan drug designation from US FDA
- Patent protection to 2035
- Phase I data in multiple relapsed ovarian cancer presented at AACR 2021* and published in *Cancers* in Q2 2021

*Full data can be found on the AACR 2021 website <https://www.aacr.org/meeting/aacr-annual-meeting-2021/>

**Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Pineros M, Znaor A, et al. Cancer statistics for the year 2020: An overview. *Int J Cancer*. 2021.

***CAGR – compound annual growth rate

**** Source: <https://www.researchandmarkets.com/reports/5319151/ovarian-cancer-drugs-global-market-report-2021>

Ovarian cancer incidence**



314k

new cases
worldwide
2020

207k

deaths
worldwide
2020

Ovarian cancer market growth****




Cantrixil – getting ready for Phase II in ovarian cancer

- **Initiation of interactions with regulators**
 - Meetings with FDA, EMA and Sweden's MPA to be held
 - Discussion of trial design, endpoints, appropriate data for filing and regulatory pathways
- **Securing study drug supply**
 - Agreement signed with Swiss specialist manufacturer Lonza for large-scale production of main drug intermediate
 - Technical transfer and scale up
- **Expanded R&D capabilities in Uppsala**
 - Capacity to develop new formulations of Cantrixil and other oncology products
- **Exploring "pipeline in a product" potential in other cancers**

Docetaxel micellar – Phase Ib in advanced prostate cancer on track

- SAKK open-label, multi-center, single-stage trial at three Swiss hospitals
- Targeting 18 chemotherapy-naive patients with **metastatic castration-resistant prostate cancer (mCRPC)**
 - First patient fully completed study (Feb 2022)
 - First of three dosing groups fully recruited
 - Third dose group underway
- Further sites may be added to accelerate recruitment



XR-17™/XR-18 – progress on next generation development

Solubilization platform expansion & enhancement


- Promising novel candidate for use with XR-18 identified and synthesized
- Testing underway with widely-used oncology compound
- Potential for improved properties and capabilities vs. XR-17™
- Agreement with Visikol Inc. to evaluate cellular effects & enable selection of promising oncology candidates

Apealea[®] – European launches underway




- Launched in Germany by Inceptua 15 August 2022
- UK commercialisation plans progressing
 - Inceptua, has secured a maximum list price for Apealea[®] with the Department of Health and Social Care, allowing private market access
 - Inceptua is engaged with NHS England to secure reimbursement
- Other European launches will be implemented on a country-by-country basis over the next couple of years
- First royalties for Vivesto are anticipated in 2023

- Germany – launched
- UK – commercialisation plans progressing



Q2 financials – a solid cash position, no debt and operating costs reduced

- Continued reduction in cashflow from operating activities MSEK -29.3 (MSEK -48.4)
- Operating loss totalled MSEK -36.3 (MSEK -56.2), a significant reduction since Q2 2021
- Short-term investments and cash and cash equivalents amounted to MSEK 188.8 (MSEK 176.3) at the end of Q2 2021
- The rights issue fully completed in Q2 raised MSEK 151 before issue expenses of MSEK 16, thereby strengthening the equity by MSEK 135, resulting in a solid financial position with an equity/assets ratio of 95% and with no debt




String of pearls strategy – leveraging our strengths

Adding new oncology programmes with cutting edge science

- Partnering
- In-licensing
- Co-development
- Early-stage assets with multiple MoA
- M&A

Application of Vivesto's core expertise



Validated by Apealea[®] development to MAA in Europe

Direct commercialization of niche products in Europe



Global collaborations

Summary

Opportunity to create a **Nordic oncology powerhouse** focused on cancers poorly served by current treatments



Capabilities and experience in place to build an oncology pipeline with focused mechanisms of action



String of pearls strategy to build critical mass



Multiple shots on goal through focused mechanisms of action targeting varied tumor types



A technology platform for innovative partners & potentially high value assets



Positioned to attract international **institutional specialist investors**



Thank you

Vivesto AB (STO: VIVE)
Vallongatan 1
752 28 Uppsala
Sweden

 +46 018-50 54 40

 IR@vivesto.com

 www.vivesto.com

 www.linkedin.com/company/vivesto-ab

 www.twitter.com/vivesto

